Biogen to Cut Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biogen to Cut Jobs

ePT--the Electronic Newsletter of Pharmaceutical Technology

Biogen to Cut Jobs

Biogen Idec (Boston, MA) said last Thursday that it would lay off approximately 17% of its workforce to reduce annual operating costs by $200–300 million.

The downsizing will be part of a restructuring plan conceived after reviews of business processes, geographic locations, and staffing. Cuts will be made at the managerial and staff level, and are expected to equate to approximately 650 jobs, mostly in the San Diego, California, area, and at the company's manufacturing operations at Research Triangle Park, North Carolina.

In addition, the company plans to sell its NICO clinical manufacturing plant in San Diego and property in Oceanside, California. Also on the chopping block is the psoriasis drug, "Amevive," which had revenue of $43 million in 2004. Biogen expects the plan to take effect by the end of the year.

Biogen Idec said that it is considering using the additional funds for new product opportunities and 'the acquisition of products and companies, as well as expanding collaborative research with academic institutions and teaching hospitals."

In related news, Biogen also announced that Michael Gilman, executive vice-president of research, is leaving the company, effective Nov. 8. Alphonse Galdes, vice-president of drug discovery, and Rainer Fuchs, vice-president of research informatics and operations, will take his place in the interim.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here